Enfermedad pulmonar intersticial asociada a rituximab / Rituximab-induced interstitial lung disease
Medicina (B.Aires)
; 73(4): 343-345, jul.-ago. 2013. ilus
Article
in Es
| LILACS
| ID: lil-694793
Responsible library:
AR1.2
RESUMEN
La introducción en la práctica clínica del anticuerpo anti-CD20 rituximab ha mejorado sustancialmente el pronóstico de diversas enfermedades autoinmunes y hematológicas. Con el incremento de su uso ha aumentado el registro de efectos adversos, entre ellos la toxicidad pulmonar. Una de sus complicaciones más serias es la enfermedad pulmonar intersticial, entidad potencialmente fatal que debe ser considerada en pacientes que han recibido rituximab y presentan disnea, fiebre y tos sin clara evidencia de infección. Presentamos un caso de enfermedad pulmonar intersticial asociada a rituximab.
ABSTRACT
The introduction of the anti-CD20 antibody rituximab into clinical practice has improved substantially the prognosis of a variety of haematological and autoimmune diseases. The interstitial lung disease is one of most serious and potentially fatal complications of rituximab therapy. This diagnosis should be considered in patients who have received the drug and present with dyspnea, fever and cough without clear evidence of infection. We report a case of rituximab-induced interstitial lung disease.
Key words
Full text:
1
Index:
LILACS
Main subject:
Lung Diseases, Interstitial
/
Antibodies, Monoclonal, Murine-Derived
/
Antineoplastic Agents
Type of study:
Prognostic_studies
Limits:
Aged
/
Female
/
Humans
Language:
Es
Journal:
Medicina (B.Aires)
Journal subject:
MEDICINA
Year:
2013
Type:
Article